Result Analysis of Erythrocyte Sedimentation Rate (ESR) For Tuberculosis (TB) Patient with Anti-Tuberculosis Drug

This research is based on information about the different and varied determination result of Erythrocyte Sedimentation Rate (ESR) from clinical laboratories in Makassar on pulmonary tuberculosis (TB) patients pre- and post-treatment with Anti-Tuberculosis drug. Determination of ESR on the diagnosis of Tuberculosis (TB) patients provides an illustration about the occurrence of inflammatory process, due to an increase in levels of fibrinogen and plasma globulin which are closely related to the presence of acute phase reactions so that causes ESRs values rise. On the other hand, it turns out that the value of ESR also increases in various conditions of infection or inflammation in some other cases of disease, so that ERS become not specific for TB. While, ESR are very useful in monitoring the success of Anti-Tuberculosis treatment. The problem of research that until now the determination of Erythrocyte Sedimentation Rate (ESR) for Tuberculosis (TB) patients the difference in the determination result of Erythrocyte Sedimentation Rate (ESR) for Tuberculosis (TB) patients pre- and post-treatment with Anti-Tuberculosis drugs is clearly unknown. The type of research is laboratory observational that aimed to determine the differences in the determination results of Erythrocyte Sedimentation Rate (ESR) for TB patients pre- and post-treatment with Anti-Tuberculosis drugs in 2 weeks at the Center for Lung Health. The population of research were TB patient TBA positive at the Center for Lung Health. The sampling uses a purposive sampling with a sample of 20 patients consisting of 10 patients (do not undergone Anti-Tuberculosis treatment) and 10 patients (undergone Anti-Tuberculosis treatment). The results of research indicate that tcount > ttable, it means H0 rejected and Ha accepted, it can be concluded that there were significant differences in the determination results of Erythrocyte Sedimentation Rate (ESR) pre- and post-treatment with Anti-Tuberculosis drugs in 2 weeks.